http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101250557-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-115 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-115 |
| filingDate | 2011-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101250557-B1 |
| titleOfInvention | PFA specific aptamers and compositions for treating pancreatic cancer comprising the same |
| abstract | The present invention relates to a PAUF specific aptamer and a composition for treating pancreatic cancer comprising the same, wherein the PAUF specific aptamer according to the present invention binds to PAUF with high affinity and specificity, and has toxicity and immunogenicity when administered in the body. Almost no, and also the results of experiments using a xenograft animal model, there is an advantage that can be useful for the treatment of pancreatic cancer as well as excellent pancreatic cancer treatment effect, without the appropriate therapeutic agent. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021010534-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200078303-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020130269-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020130225-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210009810-A |
| priorityDate | 2011-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 75.